May 20, 2013
Lumena CEO, Mike Grey, says the recent $23 million in Series A financing will fund the clinical development of LUM001, its lead product candidate for the treatment of a disorder called cholestatic liver disease.
Stories this photo appears in:
BIOTECH: PwC Reports Q1 2013 Drop In Dollars and Deals
Lumena Pharmaceuticals Inc., a San Diego-based manufacturer of liver disease drugs, recently secured $23 million in Series A financing.